Peptides are having a moment. You’ve probably heard them mentioned everywhere—podcasts, influencers, group chats. Names like semaglutide, tirzepatide, retatrutide… and BPC-157.
But what actually are peptides? And why are they suddenly getting so much attention? Let’s take a closer look.
What are peptides?
They’re short chains of amino acids (protein fragments) that act as signals in the body.
Instead of broadly affecting the body, peptides act more like messengers: telling specific systems what to do. Some regulate appetite. Others influence inflammation, healing, or hormone release.
What’s proven:
Some peptides are already well understood and widely used in medicine.
GLP-1–based treatments (like semaglutide and tirzepatide) have been studied in large clinical trials, approved by regulators, and are now widely prescribed. They’ve shown meaningful, repeatable effects on weight, blood sugar, and broader metabolic health.
What’s not (yet):
Others are much earlier—and far less certain.
Compounds like BPC-157, MOTS-c, and TB-500 are still experimental and are not authorized for sale by Health Canada, meaning their safety and efficacy has not been officially assessed. Most of the evidence comes from animal studies or small, uncontrolled trials. We don’t yet have strong data on long-term safety or effectiveness in humans.
→ Read more: The messy reality of BPC-157
TLDR: same category, very different realities. Some peptides are already reshaping medicine. Others are still catching up.
→ Watch: Humours peptide profile
